Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. - Wikidata - wikimedia - TriplyDB

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

http://www.wikidata.org/entity/Q48424510

about

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.Disease modification in epilepsy: from animal models to clinical applications.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Exploring the latest avenues for antiepileptic drug discovery and development.Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model.Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.Vitamin B6 and homocysteine levels in carbamazepine treated epilepsy of Khyber Pakhtunkhwa.Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.New hope for the treatment of epilepsy.Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs.Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+ channel inactivation.Hippocampal low-frequency stimulation inhibits afterdischarge and increases GABA (A) receptor expression in amygdala-kindled pharmacoresistant epileptic rats.Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.

P2860

Q26745780-169610BE-EEFA-40C8-919F-252A4A7395A2 Q35664957-0FC29D4F-786D-4229-88F6-012A8C14839E Q35761335-8BD5FD4A-8155-403F-93E8-B3209345DE30 Q35936036-D076555C-1C67-4BD7-A9FD-72F8D9455CFB Q37680030-43C72855-71F7-49B6-8784-55ED896B9A3E Q37694387-D518820F-FAAA-4ECF-A0B1-3788A21EAC7A Q38450069-76B1EA40-B67B-4DCD-ACD1-9EA192094FA6 Q38542064-871DCC5A-EA38-425F-981C-4B835728B400 Q38739649-773735AA-BFAC-4057-99D7-7571E37C8692 Q38754189-819F4462-DFC3-4447-9BE6-6754882B3569 Q41507254-064881EF-C68A-4AB4-B5A2-B229A851382F Q41884924-08878588-F4A6-4644-8D99-89411E427FA0 Q44168300-8477867E-B4A1-4C0D-9700-82C00E51CFFA Q47120159-338765DD-8359-4282-934E-BBA77EFCA487 Q47235722-937A6D2E-A600-4AAC-94DD-AB548EEEBA10 Q47573219-CF6438AD-62FB-4151-9654-FAEBC95D2F80 Q47797132-7B71FE8E-5DC5-462A-BDD6-A6C4B5AC8395 Q48352462-777FA846-0ACA-4646-9479-B64A449B8B50 Q48363733-C80DE7CC-7FD9-4A99-A79F-D5EA4F3BC853 Q48423763-D464942C-F6A4-439C-B065-A0561A7DCAAA Q50649503-624F262A-E259-41D0-8CD5-34FC14A0164D Q51736900-E89B09B4-6765-4A5D-B6BA-49A68C156A21

P2860

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

http://www.wikidata.org/entity/Q48424510

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@en

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@nl

type

label

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@en

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@nl

prefLabel

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@en

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@nl

P1433

Q48424510-18BD0B20-0533-4426-9A71-85C002F8CC65

P1476

Q48424510-31270405-732F-4A5E-B9B7-12E4EB17528A

P2093

Q48424510-095F397F-8487-4046-B1C1-91DC70774B6E

Q48424510-2BD26044-FC07-4B0A-B9FB-3AF1EF2C47E6

Q48424510-52B6B65A-E07E-4446-8379-401B69ECDB0E

Q48424510-65588E7A-E0C0-48AF-A518-06F64C10690C

Q48424510-7C3C221D-3B87-49AC-8EB5-79D3E109C083

Q48424510-8C9663F8-65DB-4BA7-85EE-34BCA2EBA4F9

Q48424510-9A041DE3-83F8-4282-B79A-D4DB19697FA6

Q48424510-CFEA66E3-2711-42C3-A852-C16FBBB2A486

P2860

Q48424510-04D1E2DF-8D8C-4A11-9D63-4E24408470BF

Q48424510-1F44F4BC-B2D7-4418-AA5B-F89B54AF922B

Q48424510-27C58D85-47DD-4C2D-BED5-CB7089BF215B

Q48424510-2F370864-0E63-4D54-8A5E-5E410217E5D6

Q48424510-3137429B-1A3A-4570-A62B-DBAEE9E3C28B

Q48424510-34D78382-FB90-4EB8-881A-8B34E0E567DB

Q48424510-435E00BE-3AAD-4D7C-A936-13DD5630011B

Q48424510-4579EB7E-22C0-4AB2-9C20-80DF7AAC96E0

Q48424510-531697F1-06E2-449E-AAC5-9F445C698F07

Q48424510-6475387C-1030-4A70-B7E4-652C19692803

P304

Q48424510-91A9FAD0-53A7-4A47-88C4-8BBEC4E7373D

P31

Q48424510-19025798-60CA-4395-A379-B95CA73A5E9D

P356

Q48424510-B49E3240-8678-4C38-9BAB-5DE34F1F5478

P407

Q48424510-400F983F-F22F-4812-8E77-36C936E788F5

P433

Q48424510-4DFF7B5C-677E-4C9C-8216-81CA095787C7

P478

Q48424510-23489889-8A3F-453B-80C4-9677FDE597B4

P50

Q48424510-500C8902-9353-49C5-ACF7-11F556CC50FD

P577

Q48424510-DAC6714A-5AFF-4857-A0FC-2DAD651ACC6B

P5875

Q48424510-94B39F23-35AD-41B9-A276-93917ACDF16E

P698

Q48424510-A4BB2416-8FCC-4494-9993-EC0C588900E2

P356

P1433

P1476

Targeting pharmacoresistant ep ...... al-purpose antiepileptic drug.

@en

P2093

Anna Doeser

http://www.w3.org/2001/XMLSchema#string

Christina Schaub

http://www.w3.org/2001/XMLSchema#string

Gesa Dickhof

http://www.w3.org/2001/XMLSchema#string

Heinz Beck

http://www.w3.org/2001/XMLSchema#string

Margit Reitze

http://www.w3.org/2001/XMLSchema#string

Maria João Bonifácio

http://www.w3.org/2001/XMLSchema#string

Mischa Uebachs

http://www.w3.org/2001/XMLSchema#string

Patrício Soares-da-Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging

Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects

Pharmacokinetics and drug interactions of eslicarbazepine acetate.

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.

Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

The effects of eslicarbazepine on persistent Na⁺ current and the role of the Na⁺ channel β subunits.

Voltage-gated sodium channels in epilepsy.

Mechanisms of epileptogenesis and potential treatment targets.

A novel mechanism underlying drug resistance in chronic epilepsy.

Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats.

P304

371-387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWU339

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 2

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Nuno Miguel Pires

P577

2014-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269170767

http://www.w3.org/2001/XMLSchema#string

P698

25472797

http://www.w3.org/2001/XMLSchema#string